Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Rank in Stocks #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Share Price
$5.54
Last synced: 2024-09-18
Market Cap
$38.76M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Alimera Sciences, Inc. (ALIM)

Category

P/E ratio for Alimera Sciences, Inc. (ALIM)
P/E ratio as of August 2026 TTM: -7.01
According to Alimera Sciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -7.01. At the end of 2022 the company had a P/E ratio of -1.05.
P/E ratio history for Alimera Sciences, Inc. from 2006 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -7.01 27.74%
2023 -5.49 423.80%
2022 -1.05 -86.47%
2021 -7.74 91.29%
2020 -4.05 16.84%
2019 -3.46 -10.25%
2018 -3.86 -4.74%
2017 -4.05 135.60%
2016 -1.72 -51.03%
2015 -3.51 -43.68%
2014 -6.23 94.13%
2013 -3.21 28.36%
2012 -2.50 43.63%
2011 -1.74 -92.57%
2010 -23.42 6,105.06%
2009 -0.38 30.31%
2008 -0.29 -90.72%
2007 -3.12 127.36%
2006 -1.37 0.00%
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.